Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling (Nature Cancer, (2022), 3, 11, (1336-1350), 10.1038/s43018-022-00447-1)

Ido Yofe; Tomer Landsberger; Adam Yalin; Isabelle Solomon; Cristobal Costoya; Dafne Franz Demane; Mansi Shah; Eyal David; Chamutal Borenstein; Oren Barboy; Ignacio Matos; Karl S. Peggs; Sergio A. Quezada; Ido Amit

doi:10.1038/s43018-022-00487-7

Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling (Nature Cancer, (2022), 3, 11, (1336-1350), 10.1038/s43018-022-00447-1)

Ido Yofe, Tomer Landsberger, Adam Yalin, Isabelle Solomon, Cristobal Costoya, Dafne Franz Demane, Mansi Shah, Eyal David, Chamutal Borenstein, Oren Barboy, Ignacio Matos, Karl S. Peggs, Sergio A. Quezada, Ido Amit

Research output: Contribution to journal › Comment/debate

Abstract

In

Original language	English
Pages (from-to)	1404
Number of pages	1
Journal	Nature Cancer
Volume	3
Issue number	11
DOIs	https://doi.org/10.1038/s43018-022-00487-7
State	Published - Nov 2022
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Access to Document

10.1038/s43018-022-00487-7

Fingerprint

Dive into the research topics of 'Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling (Nature Cancer, (2022), 3, 11, (1336-1350), 10.1038/s43018-022-00447-1)'. Together they form a unique fingerprint.

Cite this

Yofe, I., Landsberger, T., Yalin, A., Solomon, I., Costoya, C., Demane, D. F., Shah, M., David, E., Borenstein, C., Barboy, O., Matos, I., Peggs, K. S., Quezada, S. A., & Amit, I. (2022). Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling (Nature Cancer, (2022), 3, 11, (1336-1350), 10.1038/s43018-022-00447-1). Nature Cancer, 3(11), 1404. https://doi.org/10.1038/s43018-022-00487-7

@article{f80f47706569460e83076ddbd1b34142,

title = "Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling (Nature Cancer, (2022), 3, 11, (1336-1350), 10.1038/s43018-022-00447-1)",

abstract = "In",

author = "Ido Yofe and Tomer Landsberger and Adam Yalin and Isabelle Solomon and Cristobal Costoya and Demane, \{Dafne Franz\} and Mansi Shah and Eyal David and Chamutal Borenstein and Oren Barboy and Ignacio Matos and Peggs, \{Karl S.\} and Quezada, \{Sergio A.\} and Ido Amit",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Nature America, Inc. 2022.",

year = "2022",

month = nov,

doi = "10.1038/s43018-022-00487-7",

language = "الإنجليزيّة",

volume = "3",

pages = "1404",

journal = "Nature Cancer",

issn = "1474-175X",

publisher = "Nature Publishing Group",

number = "11",

}

Yofe, I, Landsberger, T, Yalin, A, Solomon, I, Costoya, C, Demane, DF, Shah, M, David, E, Borenstein, C, Barboy, O, Matos, I, Peggs, KS, Quezada, SA & Amit, I 2022, 'Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling (Nature Cancer, (2022), 3, 11, (1336-1350), 10.1038/s43018-022-00447-1)', Nature Cancer, vol. 3, no. 11, pp. 1404. https://doi.org/10.1038/s43018-022-00487-7

Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling (Nature Cancer, (2022), 3, 11, (1336-1350), 10.1038/s43018-022-00447-1). / Yofe, Ido; Landsberger, Tomer; Yalin, Adam et al.
In: Nature Cancer, Vol. 3, No. 11, 11.2022, p. 1404.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Author Correction

T2 - Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling (Nature Cancer, (2022), 3, 11, (1336-1350), 10.1038/s43018-022-00447-1)

AU - Yofe, Ido

AU - Landsberger, Tomer

AU - Yalin, Adam

AU - Solomon, Isabelle

AU - Costoya, Cristobal

AU - Demane, Dafne Franz

AU - Shah, Mansi

AU - David, Eyal

AU - Borenstein, Chamutal

AU - Barboy, Oren

AU - Matos, Ignacio

AU - Peggs, Karl S.

AU - Quezada, Sergio A.

AU - Amit, Ido

PY - 2022/11

Y1 - 2022/11

N2 - In

AB - In

UR - http://www.scopus.com/inward/record.url?scp=85141987026&partnerID=8YFLogxK

U2 - 10.1038/s43018-022-00487-7

DO - 10.1038/s43018-022-00487-7

M3 - تعليقَ / نقاش

C2 - 36376510

SN - 1474-175X

VL - 3

SP - 1404

JO - Nature Cancer

JF - Nature Cancer

IS - 11

ER -

Yofe I, Landsberger T, Yalin A, Solomon I, Costoya C, Demane DF et al. Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling (Nature Cancer, (2022), 3, 11, (1336-1350), 10.1038/s43018-022-00447-1). Nature Cancer. 2022 Nov;3(11):1404. doi: 10.1038/s43018-022-00487-7

Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling (Nature Cancer, (2022), 3, 11, (1336-1350), 10.1038/s43018-022-00447-1)

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this